Similarly, in patients with non-alcoholic steatohepatitis, FGF21 analogues ameliorate hepatic steatosis, liver stiffness and biomarkers of liver fibrosis (26), however the long-term effects of FGF21 in clinical outcomes remain unknown. This evidence concerns the gene FGF21 and Hepatic fibrosis.